The Week In Cannabis: Canada Funds Research, EU Country Allows Sale Of CBD, NFL Moves Forward – Benzinga

This week, lawmakers, cannabis entrepreneurs, investors, and other influential people gathered in Washington D.C. for KCSA’s Congressional Cannabis Day Forum. Speakers included Rep. Earl Blumenauer, CNBC’s Tim Seymour, Rep. David Joyce, Rep. Barbara Lee and Rep. Don Young.

In other big news, the National Football League and the NFL Players Association reached an agreement to study the possible use of cannabis by players to treat pain; the Canadian government announced it is setting aside about CA$25 million ($18.5 million) to fund cannabis research; and Bulgaria became the first European Union country to issue a Free Sale Certificate for CBD products, setting an important precedent for the region.

On the financial front, Square Inc (NYSE: SQ) confirmed that it has a pilot program underway to allow select hemp-derived CBD products on its platform. “Square is currently conducting an invite-only beta for some CBD products,” a Square spokesperson told Benzinga.

OrganiGram Holdings (NASDAQ: OGI) listed on the Nasdaq and The Flowr Corporation (OTC: FLWPF) was approved to trade on the same exchange soon, although the exact date “won’t be set until the SEC formalizes the 40-F registration statement,” Green Market Report CEO Debra Borchardt told Benzinga.

“This is definitely a sign that the NASDAQ is easing up on its resistance to cannabis companies. In addition to that, the exchange has also begun to allow Green Market Report to interview these listed companies as the barriers toward cannabis-focused media begin to fall. It’s great to see this warming relationship to the industry.”

Subscribe to if you want to receive links to this recap every week.

In the wake of a lawsuit filed against Facebook Inc (NASDAQ: FB), the social media behemoth held a product policy meeting to review its stance on cannabis. The company ultimately decided to maintain its stance against marijuana advertising on its social

Read More Here...

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top